Open AccessDual Action Mechanism of Insulin Resistance and Insulin Secretion by Imeglimin for Diabetic Treatment
Author(s) -
Hiroshi Bando
Publication year - 2022
Publication title -
diabetes research
Language(s) - English
Resource type - Journals
ISSN - 2379-6375
DOI - 10.17140/droj-8-e017
Subject(s) - insulin , insulin resistance , medicine , endocrinology , mechanism of action , diabetes mellitus , glucagon like peptide 1 , receptor , pancreatic hormone , secretion , type 2 diabetes , pharmacology , biology , in vitro , biochemistry
Imeglimin (Twymeeg) is novel oral hypoglycemic agent (OHA) developed in the glimin category. It has dual action mechanisms of reducing insulin resistance and increasing insulin secretion. Trials of imeglimin for efficacy and safety 1 (TIMES 1), TIMES 2 and TIMES 3 were performed with significant clinical efficacy. Among them, HbA1c decrease for 52 weeks showed single imeglimin -0.46%, combined therapy of dipeptidyl peptidase-4i (DPP-4i)-0.92%, Glucagon-like peptide-1 receptor agonists (GLP-1RA)-0.12% and insulin -0.63%. From physiological and pharmacological points of view, the mechanism may include the enhancement action of glucose-stimulated insulin secretion (GSIS). For GSIS progress, transient receptor potential melastatin 2 (TRPM2) channel is activated.